5819-19-2

Basic information

• Product Name: Benzoicacid1-chloroethylester
• Synonyms: Benzoicacid1-chloroethylester;1-CHLOROETHYL BENZOATE;1-Chloroethyl esterbenzoic acid
• CAS NO: 5819-19-2
• Molecular Formula: C₉H₉ClO₂
• Molecular Weight: 184.61956
• Mol File: 5819-19-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 268.997°C at 760 mmHg
• Flash Point: 129.692°C
• Appearance: /
• Density: 1.187g/cm³
• Vapor Pressure: 0.007mmHg at 25°C
• Refractive Index: 1.522
• CAS DataBase Reference: Benzoicacid1-chloroethylester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoicacid1-chloroethylester(5819-19-2)
• EPA Substance Registry System: Benzoicacid1-chloroethylester(5819-19-2)

Safety Data

• Hazardous Substances Data: 5819-19-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H9ClO2/c1-7(10)12-9(11)8-5-3-2-4-6-8/h2-7H,1H3

Upstream product

• 769-78-8 vinyl benzoate 
• 98-88-4 benzoyl chloride 
• 75-07-0 acetaldehyde 
• 123-63-7 paracetaldehyde 
• 7647-01-0 hydrogenchloride 

Downstream Products

• 141871-99-0 1-(Benzoyloxy)ethyl 4-{N-butyl-N-[(2'-[1H-tetrazol-5-yl]biphenyl-4-yl)methyl]amino}pyrimidine-5-carboxylate 
• 769-78-8 vinyl benzoate 
• 1391034-27-7 C₁₂H₁₄O₃S₂ 
• 141872-48-2 1-(Benzoyloxy)ethyl 4-{N-butyl-N-[(2'-[N-triphenylmethyl-1H-tetrazol-5-yl]biphenyl-4-yl)methyl]amino}pyrimidine-5-carboxylate 
• 666174-90-9 (S)-1-chloroethyl benzoate 
• 666174-89-6 (R)-benzoic acid 1-chloroethyl ester 
• 103312-98-7 2-<(2-pyridinylmethyl)sulfinyl>-1H-benzimidazole-1-ethan-2-ol benzoate 
• 581106-33-4 [3-[acetyl(phenylmethoxy)amino]propyl]-phosphonic acid bis[1-(benzoyloxy)ethyl] ester 
• 132750-16-4 Benzoic acid 1-[2-(pyridin-2-ylmethylsulfanyl)-benzoimidazol-1-yl]-ethyl ester 
• 52571-16-1 1-iodoethyl benzoate 

Relevant articles and documents

Method for synthesizing vinyl carboxylate

The present invention relates to a method for synthesizing carboxylic acid enol esters, in particular to a method for synthesizing vinyl carboxylate. The vinyl carboxylate is prepared by performing asynergistic reaction on a 1-chloroethyl carboxylate represented by a formula 1 and an epoxy compound under the effect of a metal chloride catalyst. In 1-chloroethyl carboxylate represented by the formula 1, n is a natural number larger than or equal to 1, when n=1, the 1-chloroethyl carboxylate includes monocarboxylates in which R represents a hydrocarbon group or a hetero-hydrocarbon group containing carbonyl, an ether bond, a thioether bond, an ester bond, or a peptide bond, and when n is equal to or larger than 2, the 1-chloroethyl carboxylate ester includes di(1-chloroethyl) oxalate and polycarboxylates in which R is a hydrocarbon group or a hetero-hydrocarbon group containing carbonyl, an ether bond, a thioether bond, an ester bond and a peptide bond. Compared with a vinyl acetate exchange method, the synergic method has a lower cost, and the process design is simple and suitable for industrial production. The vinyl carboxylate has a wide range of uses in the field of polymer synthesis and coatings.

COMPOUNDS AND THERAPEUTIC USES THEREOF

The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.

Prodrugs of perzinfotel with improved oral bioavailability

Previous studies with perzinfotel (1), a potent, selective, competitive NMDA receptor antagonist, showed it to be efficacious in inflammatory and neuropathic pain models. To increase the low oral bioavailability of 1 (3-5%), prodrug derivatives (3a-h) were synthesized and evaluated. The oxymethylene-spaced diphenyl analogue 3a demonstrated good stability at acidic and neutral pH, as well as in simulated gastric fluid. In rat plasma, 3a was rapidly converted to 1 via 2a. Pharmacokinetic studies indicated that the amount of systemic exposure of 1 produced by a 10 mg/kg oral dose of 3a was 2.5-fold greater than that produced by a 30 mg/kg oral dose of 1. Consistent with these results, 3a was significantly more potent and had a longer duration of activity than 1 following oral administration in a rodent model of inflammatory pain. Taken together, these results demonstrate that an oxymethylene-spaced prodrug approach increased the bioavailability of 1.